Aclaris Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $225.3M | $20.2M |
| FY2018 | $29.9M | $215.1M | $57.0M |
| FY2019 | — | $69.9M | $34.2M |
| FY2020 | $10.7M | $37.7M | $22.1M |
| FY2021 | — | $197.3M | $27.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $225.3M | $20.2M |
| FY2018 | $29.9M | $215.1M | $57.0M |
| FY2019 | — | $69.9M | $34.2M |
| FY2020 | $10.7M | $37.7M | $22.1M |
| FY2021 | — | $197.3M | $27.3M |